Innocoll is dedicated to making better happen — finding solutions to help patients reduce pain associated with surgeries and to treat limb-threatening infections.
Our proprietary, biocompatible, and biodegradable collagen-based products are engineered for targeted use. Applied locally to wound and/or surgery sites, they are designed to provide a range of treatment benefits.
Our late-stage product pipeline is focused on addressing a number of significant unmet medical needs: INL-001, bioresorbable bupivacaine HCI collagen-matrix implants (Phase III completed), in development for postsurgical analgesia; INL-002, a gentamicin collagen-matrix patch, in development for the treatment of diabetic foot infections (Phase III completed); and INL-003, a bioresorbable collagen film surgical adhesion barrier (approved ex-US), in development for the prevention of postsurgical adhesions.
Our currently approved products include: COLLAGUARD® (ex-US), COLLATAMP® G, SEPTOCOLL® E, REGENEPRO®, COLLACARE®, COLLEXA®, and ZORPREVA®, some of which are sold globally through strategic partnerships. All of our collagen products—from extraction/purification of Type 1 collagen through final delivery— are manufactured at our certified, integrated plant in Saal, Germany.
Our Pipeline Products
“As we look toward the future, the success of Innocoll is predicated on continuing to deliver inspired innovation through targeted solutions that help make today’s medicines work better. By designing innovative site-specific treatment options, we’re bringing that vision to light: improving patient lives and enhancing outcomes—and fulfilling our promise of making better happen.”
– Anthony Zook, CEO, Innocoll